Skip to Main Content

Paper Details

Metabolomic architecture of obesity implicates metabolonic lactone sulfate in cardiometabolic disease.
Mol Metab
4
2021
/CYP3A5 locus, CYP3A5, CYP3A53, DBP, IRASFS, Insulin, Insulin Resistance Atherosclerosis, PAA, PAI-1, X-12063, ZSCAN25, cardiometabolic disease, hip, insulin, lactone, lactone sulfate, metabolonic lactone sulfate, obesity, plasminogen activator inhibitor-1, rs776746, sulfate, triglycerides
Author NameAffiliation
Maggie C Y NgVanderbilt Genetics Institute, Vanderbilt University Medical Center
Jill M NorrisColorado School of Public Health
Yii-Der Ida ChenThe Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-university of california los angeles Medical Center
Lynne E WagenknechtWake Forest School of Medicine
Donald W BowdenWake Forest School of Medicine
Kent D TaylorThe Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-university of california los angeles Medical Center
Carl D LangefeldWake Forest School of Medicine
Carl D LangefeldWake Forest School of Medicine
Nicholette D PalmerWake Forest School of Medicine
  • 1 - 9

Datasets

Release 1.2